dr. weber on nivolumab in the adjuvant setting for melanoma
Published 6 years ago • 133 plays • Length 1:15Download video MP4
Download video MP3
Similar videos
-
2:10
dr. weber on the toxicity profile of nivolumab versus ipilimumab for melanoma
-
1:16
nivolumab in the adjuvant setting for melanoma
-
7:34
adjuvant therapy for melanoma: nivolumab, pembrolizumab, ipilimumab, dabrafenib and trametinib
-
1:22
dr. weber on nivolumab versus chemotherapy in advanced melanoma
-
1:22
dr. weber on adjuvant pembrolizumab in melanoma
-
0:59
dr. weber on the fda approval for fixed-dose of nivolumab
-
24:47
adjuvant and neoadjuvant therapy for melanoma weber 2021
-
2:05
dr. weber on adjuvant approaches in stage iii melanoma
-
2:05
dr. jeffrey weber explores nivolumab in advanced melanoma
-
2:25
dr. weber on discontinuing immunotherapy in melanoma
-
1:03
dr. weber on risk and benefits with immunotherapy combos in melanoma
-
1:49
dr. luke on the fda approval of adjuvant nivolumab in melanoma
-
1:05
dr. weber on rationale for the checkmate-238 trial in melanoma
-
1:28
dr. jeffery s. weber on sequencing of nivolumab, ipilimumab in metastatic melanoma
-
7:03
adjuvant therapy for melanoma
-
1:17
dr. weber on checkmate-238 compared to other trials in melanoma
-
1:14
dr. weber discusses advancements in melanoma
-
1:46
dr. weber on selecting immunotherapy for patients with melanoma
-
4:59
adjuvant therapy options in melanoma